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Abstract
Background: Botulinum toxin blocks acetylcholine release from nerve endings and acts as a long
term, reversible inhibitor of muscle contraction as well as of salivary, sweat gland, adrenal and
prostatic secretions. The aim of the present study is to investigate whether gastric submucosal
injection of botulinum toxin type A reduces stimulated gastric production of HCl.
Methods: Sixty-four rats were randomized in two groups and laparotomized. One group was
treated with botulinum toxin-A 10 U by multiple submucosal gastric injections, while the second
group was injected with saline. Two weeks later, acid secretion was stimulated by pyloric ligation
and acid output was measured. Body weight, food and water intake were also recorded daily.
Results: HCl production after pyloric ligation was found to be significantly lower in botulinum
toxin-treated rats (657 ± 90.25 micromol HCl vs. 1247 ± 152. P = 0.0017). Botulinum toxin-treated
rats also showed significantly lower food intake and weight gain.
Conclusions: Botulinum toxin type A reduces stimulated gastric acidity. This is likely due either
to inhibition of the cholinergic stimulation of gastric parietal cells, or to an action on the myenteric
nervous plexuses. Reduction of growth and food intake may reflect both impaired digestion and
decreased gastric motility.
Background
Botulinum toxin is produced by the bacterium Clostrid-
ium botulinum in seven serotypes (A through G). It is the
most powerful known inhibitor of muscular contraction
and acts by interfering with acetylcholine release in the
neuromuscular plaque [1]. When ingested, botulinum
toxin can lead to the form of food poisoning known as
botulism; however, it is also a highly effective medication
in patients with neural and muscular disorders. When the
toxin is injected directly into the muscle, the resultant
inhibition of muscle contraction is selective, prolonged
and reversible. The effect begins 2–5 days after the injec-
tion, reaches its maximum in 7–10 days and lasts 1–2
months depending on the dose. Btx-A binds to a mem-
brane receptor in the cholinergic nerve-ending and enters
the fiber, where the active part of the toxin hydrolyses
SNAP-25. This protein is a 206-aminoacid hydrophilic
protein participating in the SNARE "fusion machine",
which binds and merges vescicular and plasma mem-
branes, eventually releasing neuromediators in the
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synaptic cleft. By removing a 9 aminoacid residue from
SNAP-25, Btx-A determines neuromuscular paralysis.
Since 1973, botulinum toxin type A (Btx-A) has been suc-
cessfully used in the treatment of voluntary muscle con-
traction disorders, such as strabismus, dystonia, tremors.
In particular, in the last decade, clinical studies have
described the therapeutic use of Btx-A in some hyperki-
netic diseases of the gastrointestinal tract (GIT) [2–4].
Since 1992, the toxin has been successfully used in acha-
lasia patients, particularly poor surgical risk subjects. In
1994 our group described the effect of Btx-A in patients
with fissure-in-ano, a disease related to the hypertonus of
the internal (smooth) anal sphincter [5,6].
The action of Btx-A is not limited to the neuromuscular
junction, as reported in other studies where autonomic
neuroglandular transmission was found to be affected.
Parotid, submandibular, nasal and sweat glands were
shown to reduce consistently their secretion after local
injection of the toxin, and the molecule has recently been
proposed as a therapeutic option in sialorrhea, in Frey's
syndrome and in the hyperhydrosis of the armpit and
hand palms [7–12]. Btx-A was also reported to reduce the
zymogen secretion from pancreas [13,14].
The motility and the secretory activity of the gastroenteric
system depend upon many neuromediators and modula-
tors. Acid secretion is regulated by a cholinergic neuron
that causes direct stimulation of the parietal cell [15].
Pyloric ligation powerfully stimulates gastric acid secre-
tion in rats, as demonstrated in well-known experiments
[16].
As botulinum toxin selectively inhibits cholinergic neural
transmission, we tested the hypothesis that prior treat-
ment with botulinum toxin would reduce the ability of rat
stomachs to secrete acid after stimulation.
Methods
Surgical procedure
The experiment was approved by local Ethics Committee.
Sixty-four adult Wistar male rats (weight 240–470 g) were
randomized into a BTX group (32 rats) and a SALINE
group (32 rats). At time 0, anaesthesia was performed
with intraperitoneal injections of diazepam (2 mg Kg-1)
and ketamine (2 mg Kg-1). Through a midline abdominal
incision the stomach was exposed and entered along the
large curve. In the BTX group, the submucosa of the gastric
fundus and corpus (not the rumen) was injected with Btx-
A (Botox; Allergan, Inc., Irvine, CA, U.S.A.) 10 U in 1 mL
saline, via four small injections using a 30G needle. The
SALINE group was treated with saline in the same fashion.
To prevent postoperative dehydration, animals were
injected with 5 cc saline subcutaneously on their back.
From the first post-operative day (day 1) rats were housed
singly in cages and allowed to feed ad libitum (standard
dry pellet diet). Body weights, weight of ingested food and
milliliters of water intake were measured and recorded
every day; on day 13, all rats were starved. On day 14, the
rats were anaesthetized, and the pylorus was exposed and
ligated through a small laparotomy. The abdominal wall
was closed and 5 cc saline were injected subcutaneously.
Access to water and food was denied. Four hours later a
lethal dose of anaesthetic was given intraperitoneally.
Esophagus and duodenum were clipped, the stomach was
removed and gastric juice collected. 10 rats (7 BTX and 3
SALINE) died within the course of the two weeks.
Chemical procedure
Collected gastric juice was centrifuged (15 minutes at
4000 rpm). The supernatant was measured and titrated
with NaOH to obtain the total acid output as µEq in 4
hours.
Statistics and Modeling
In order to evaluate the significance of the overall differ-
ence between the means of the two groups (BTX vs.
SALINE), an analysis of variance was conducted on the
HCl production of each rat.
The time-course of body weight for each rat was fitted by
a piecewise linear regression model: the model assumes a
linear trend of body weight decreasing from day 0 until
the nadir and increasing thereafter, i.e w(t) = w0 + kd t, 0 =
t = tn; and w(t) = wn + kg (t - tn), t >tn; where w [g] is the
weight of the rat as a function of time, w0 [g] is the initial
weight of the rat, wn [g] is the weight of the rat at the nadir
(lowest predicted weight after surgery), kd [g day-1] is the
rate of weight loss in the first phase, t [day] is the time, tn
[day] is the time needed to reach the nadir weight, kg [g day-
1] is the rate of weight gain in the second phase. Since wn
= w0 + kd tn, the model has three free parameters: kd, kg and
tn.
Linear regression analysis over time was also performed
on observations of time and food and water intake on
each rat, to yield estimated values of the model's parame-
ter  kfood  and  kwater  (rate of food and water intake)
respectively.
Results
The sample averages, standard deviations and the signifi-
cance of the difference of HCl production between groups
are given in Table 1. A significant difference (P < 0.002)
results between the two groups, HCl total production
being significantly lower in BTX rats.
Rate of body weight loss after surgery was faster, nadir
time was later and rate of after-nadir weight gain was
slower in BTX treated than in control animals (allBMC Gastroenterology 2003, 3 http://www.biomedcentral.com/1471-230X/3/26
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differences highly significant). Even if rats were not signif-
icantly differing in body weight at baseline, the three
effects above translate into a depressed weight recupera-
tion of BTX rats after surgery. The average time courses of
body weight for both groups are shown in Figure 1. The
difference in the time course of body weight was paral-
Table 1: BTXvs. SALINE HCl production, body weight time-course parameters, food and water intake rates.
BTX group SALINE group P
HCl production [µEq/4 hrs] 657.031 ± 848.735
(n = 24 *)
1246.645 ± 442.128
(n = 29)
<0.002
basal body-weight [g] 343 ± 51.65
(n = 26)
350 ± 48.95
(n = 29)
N.S.
kd: rate of weight loss after treatment [g day-1] -2.326 ± 1.607
(n = 26)
-0.3739 ± 0.8827
(n = 29)
<0.0001
kg: rate of weight gain after nadir [g day-1] 2.003 ± 1.583
(n = 26)
3.423 ± 1.593
(n = 29)
<0.0025
tn: days from time 0 to nadir of body weight [day] 2.45 ± 1.13
(n = 26)
1.374 ± 1.382
(n = 29)
<0.004
kfood: rate of food intake after treatment [g day-1] 20.016 ± 4.99
(n = 26)
26.881 ± 2.896
(n = 29)
<0.0001
kwater: rate of water intake after treatment [g day-1] 38.619 ± 5.325
(n = 26)
51.868 ± 11.378
(n = 29)
<0.05
* Two test tubes broke during centrifugation and datas were not available for HCl measurement.
Time course of mean daily percentage variation of body weight in BTX and SALINE groups Figure 1
Time course of mean daily percentage variation of body weight in BTX and SALINE groups. Only survivors at day 14 were con-
sidered. 100% means basal body weight of each rat.
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leled by a significant difference in food and water con-
sumption rates, Btx-A-treated rats eating and drinking less
than control rats. Time courses of food and water intake
for both groups are shown in Figures 2 and 3.
Discussion
In the present study, after pre-treatment of experimental
animals with Btx-A, the technique of pyloric ligation was
adopted. Basically, the mechanism involves vago-vagal
reflexes induced by activated mucosal baroceptors in the
antrum [17], while non-cholinergic mediators (histamin
and gastrin) seem to be less involved [18].
Membrane muscarinic receptors were described on the
basolateral plasma membrane of parietal cells, confirm-
ing the cholinergic innervation of HCl secretory cells
[19,20].
The significant reduction of stimulated acid output in Btx-
A treated rats is consistent with the hypothesized block of
neuro-glandular transmission in the parietal cells of gas-
tric mucosa. In 1977 Kondo and Magee observed that i.v.
botulinum toxin could inhibit the pentagastrin induced
and in a lesser extent the histamine induced gastric acid
secretion [21]. They also noted that acid response to vagal
stimulation was, as expected, abolished while that to
methacoline was inaltered. These observation confirm
that botulinum toxin doesn't damage the secreting cells,
but acts reversibly inhibiting acetylcholine release. Its
action is probably so effective on gastric HCl production,
because suppressing the cholinergic signal most of the
pathways that conduce to acid secretion are all inhibited.
Body weight loss was observed in both groups of rats dur-
ing the first days after surgery, as a likely consequence of
surgical stress. After a few days, SALINE-treated rats were
again growing at a normal rate. On the contrary, BTX-
treated rats showed persistently lower growth rates, paral-
leling decreased caloric intake.
The effect is highly reproducible, both in adult and (to a
lesser extent) in juvenile animals. Infact in a previous
Time course of mean daily food intake in BTX and SALINE groups Figure 2
Time course of mean daily food intake in BTX and SALINE groups. Only survivors at day 14 were considered.
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study we hypothesized that gastric peristalsis would be
impaired and food intake consequently decreased. Some
X-rays films of rats fed with contrast showed prolonged
gastric emptying times in comparison with non-treated
rats [22]. In the present study, the time course of body
weight was studied with the aid of a suitable mathemati-
cal model, allowing us to quantify a first weight loss phase
(which lasts a few days after injection in treated rats) and
a second weight gain phase. In the present series, BTX-
treated rats had steeper and more prolonged weight loss,
as well as slower subsequent weight gain, compared to
control animals. The observed effect on body weight
might be related to impaired digestive ability, mediated
by the inhibition of gastric acid secretion and possibly by
other mechanisms.
Conclusions
Btx-A is a potent neuromuscular toxin: when injected in
muscle, it reduces the strength of contraction in a dose-
dependent manner. The effect is long lasting (1–3
months), reversible, free of major side effects.
The nervous system of the gastrointestinal tract consists of
a very rich neuronal network which is organized in gan-
gliar and agangliar plexuses, like the Meissner's and Auer-
bach's plexuses controlling motility, secretion, absorption
and muscolaris mucosae activity.
Since gastric HCl secretion is strongly dependent upon
cholinergic activity of vagal and myenteric fibers which
ultimately act by their neuroglandular junctions, it was
reasonable to suppose it could be inhibited by local injec-
tion of Btx-A [23,24]. Gastric acid secretion was induced
by the pyloric ligation technique a proven, powerful stim-
ulus of acid secretion. Interestingly, this effect is reduced
by vagotomy, vagolytic agents or gangliar blocking agents,
i.e. by anti-cholinergic maneuvers. The observed effect on
stimulated acid output after submucosal injection of Btx-
A is consistent with the hypothesized impairment of
neuro-glandular cholinergic transmission. It is also possi-
ble that neural stimulation was impaired at the level of
myenteric plexuses, where neuro-neuronal synapses are
abundant. The injection of toxin was strictly submucosal,
Time course of mean daily water intake in BTX and SALINE groups Figure 3
Time course of mean daily water intake in BTX and SALINE groups. Only survivors at day 14 were considered.
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but, since the molecule has diffusive properties, the
involvement of fibers of the plexuses cannot be excluded,
at least with regards to the internal plexus.
Further studies are warranted to define the site of action of
Btx-A in the gastric neural network, and consequently
explain the observed effects. However, the present work
demonstrates that, whatever the ultimate cause of the
weight loss, mucosal Btx-A injection significantly affects
the mechanism of gastric acid production and determines
prolonged weight loss in experimental animals.
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